Volume 25, Number 11—November 2019
Availability of Injectable Antimicrobial Drugs for Gonorrhea and Syphilis, United States, 2016
We estimated the availability of the injectable antimicrobial drugs recommended for point-of-care treatment of gonorrhea and syphilis among US physicians who evaluated patients with sexually transmitted infections in 2016. Most physicians did not have these drugs available on-site. Further research is needed to determine the reasons for the unavailability of these drugs.
Rates of sexually transmitted infections (STIs) are on the rise in the United States. Compared with the incidence in 2013, the numbers of reported gonorrhea (+75%) and syphilis (primary and secondary, +153%) cases in 2017 were dramatically increased (1). Timely (optimally same-day) treatment of bacterial STIs with a highly effective regimen is critical for national STI control efforts and can help mitigate the development of drug resistance, a particularly pertinent issue for Neisseria gonorrhoeae (2). In addition, the high number of congenital syphilis cases in the United States in 2017 highlights the need for efficient and effective treatment of Treponema pallidum infection (3).
The recommended first-line treatment for uncomplicated gonorrhea is intramuscular ceftriaxone (250 mg) and for primary and secondary syphilis is intramuscular penicillin G benzathine (2.5 million units) (4). On-site access to these injectable medications in clinics facilitates point-of-care treatment and helps mitigate drug resistance to N. gonorrhoeae and T. pallidum when these drugs are used instead of the oral antimicrobial drug alternatives. Therefore, we set out to determine a nationally representative estimate of the availability of these medications and examine if differences existed by geographic location and between offices designated and not designated as patient-centered medical homes (PCMHs).
We used the 2016 Physician Induction File of the National Ambulatory Medical Care Survey (5) to assess the number of physicians who treat patients with STIs and had injectable antimicrobial drugs available on-site. The Physician Induction File is a nationally representative survey of office-based, nonfederal physicians in the United States and includes information regarding practice characteristics and habits. Use of these data is restricted, and access is facilitated through the Research Data Center, National Center for Health Statistics, Centers for Disease Control and Prevention, in Hyattsville, Maryland, USA. A total of 1,030 physicians (46.2% unweighted response rate), representing an estimated of 330,581 (95% CI 326,994–334,168) physicians in the United States, completed the Physician Induction File in 2016. In this survey, physicians who reported evaluating or treating patients for STIs were asked which antimicrobial drugs they had available on-site for same-day management of gonorrhea and syphilis, including intramuscular ceftriaxone and penicillin G benzathine at the recommended doses. We determined national estimates of reported on-site, same-day availability for these antimicrobial drugs and stratified results by PCMH designation and US region. We used multiple logistic regression models to determine if PCMH designation and region were predictive of on-site availability of these 2 medications.
An estimated 45.2% (149,483, 95% CI 138,850–160,116) of office-based physicians indicated that they evaluate patients for STIs in their offices. Of these, 77.9% (116,479, 95% CI 105,360–127,598) reported not having penicillin G benzathine available on-site and 56.1% (83,827, 95% CI 73,709–93,945) reported not having ceftriaxone. Access to both of these drugs was generally higher in the South (Table). Physicians in offices not designated PCMHs were more likely than those in offices designated PCMHs to report lacking on-site availability of ceftriaxone (odds ratio 2.03, 95% CI 1.15–3.57) and penicillin G benzathine (odds ratio 3.20, 95% CI 1.63–6.29) (Table).
Our nationally representative analysis demonstrates that most office-based physicians who provide STI services reported not having on-site access to the recommended injectable medications for gonorrhea and syphilis management. The PCMH designation has been noted as an indicator for quality of care by the American Medical Association (6) and thus might be an indication for greater access to more complex treatments and supplies, such as injectable antimicrobial drugs. In addition, previous research has found that PCMHs have larger provider staffs and are affiliated with larger medical groups or health systems that may have access to greater resources, characteristics that might result in these practices having greater access to injectable medications to treat gonorrhea and syphilis patients (7). Differences in drug availability by region were not statistically significant; however, we note that the point estimates of on-site availability were highest among physicians in areas with the highest levels of STIs (the southern United States) and where congenital syphilis has been most commonly observed (the western United States) (1).
We provide a national estimate of the percentage of US physicians treating patients with STIs that report not having the recommended antimicrobial drugs on-site for same-day treatment of gonorrhea and primary and secondary syphilis. In light of our findings, we believe that future research should focus on determining the factors preventing physicians from providing these medications on-site. The costs of obtaining and carrying these medications, as well as issues of storage and shelf life, should be explored to determine if these factors are barriers. In addition, the implications of prescribing alternative treatments or delaying care in situations when medications are not readily available on-site should be further explored. Mitigating the lack of medication availability to treat these infections will help public health officials stop the rise in STI disease.
Dr. Pearson is a health scientist working in the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. His research interests include the organization, financing, and delivery of health services.
- Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. Atlanta: US Department of Health and Human Services; 2018.
- Kirkcaldy RD, Bolan GA, Wasserheit JN. Cephalosporin-resistant gonorrhea in North America. JAMA. 2013;309:185–7. DOIPubMedGoogle Scholar
- Nurse-Findlay S, Taylor MM, Savage M, Mello MB, Saliyou S, Lavayen M, et al. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews. PLoS Med. 2017;14:
e1002473. DOIPubMedGoogle Scholar
- Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(No. RR-3):1–137.PubMedGoogle Scholar
- Centers for Disease Control and Prevention National Center for Health Statistics. Ambulatory health care data. 2019 Jul 3 [cited 2019 May 29]. https://www.cdc.gov/nchs/ahcd/index.htm
- American Medical Association. Principles of the patient-centered medical home H-160.919. 2018 [cited 2019 May 29]. https://policysearch.ama-assn.org/policyfinder/detail/Principles%20of%20the%20Patient-Centered%20Medical%20Home%20H-160.919?uri=%2FAMADoc%2FHOD.xml-0-734.xml
- McHugh M, Shi Y, Ramsay PP, Harvey JB, Casalino LP, Shortell SM, et al. Patient-centered medical home adoption: results from aligning forces for quality. Health Aff (Millwood). 2016;35:141–9. DOIPubMedGoogle Scholar
TableCite This Article
Original Publication Date: October 16, 2019
Table of Contents – Volume 25, Number 11—November 2019
|EID Search Options|
|Advanced Article Search – Search articles by author and/or keyword.|
|Articles by Country Search – Search articles by the topic country.|
|Article Type Search – Search articles by article type and issue.|
Please use the form below to submit correspondence to the authors or contact them at the following address:
William S. Pearson, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E-80, Atlanta, GA 30329-4027, USA